Journal article

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Min Jun, Katie Harris, Hiddo JL Heerspink, Sunil V Badve, Meg J Jardine, Stephen Harrap, Pavel Hamet, Michel Marre, Neil Poulter, Sradha Kotwal, Martin Gallagher, Vlado Perkovic, John Chalmers, Mark Woodward

DIABETES OBESITY & METABOLISM | WILEY | Published : 2021

Abstract

There are limited data on whether estimated glomerular filtration rate (eGFR) variability modifies the risk of future clinical outcomes in type 2 diabetes (T2D). We assessed the association between 20-month eGFR variability and the risk of major clinical outcomes in T2D among 8241 participants in the ADVANCE trial. Variability in eGFR (coefficient of variation [CVeGFR ]) was calculated from three serum creatinine measurements over 20 months. Participants were classified into three groups by thirds of CVeGFR : low (≤6.4; reference), moderate (>6.4 to ≤12.1) and high (>12.1). The primary outcome was the composite of major macrovascular events, new or worsening nephropathy and all-cause mortali..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

The ADVANCE trial was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia and from Servier. MJ is supported by a Scientia Fellowship from the University of New South Wales (Sydney, Australia). MW is supported by a National Health and Medical Research Council of Australia Investigator Grant and Program Grant.